Cargando…
Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs
BACKGROUND: Serum-based parameters are considered non-invasive biomarkers for cancer detection. In human studies, insulin-like growth factor-I and II (IGF-I and IGF-II) and insulin-like growth factor binding protein-3 (IGFBP-3) are useful as diagnostic or prognostic markers and potential therapeutic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Veterinary Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636663/ https://www.ncbi.nlm.nih.gov/pubmed/34697923 http://dx.doi.org/10.4142/jvs.2021.22.e77 |
_version_ | 1784608573446160384 |
---|---|
author | Song, Doo-Won Ro, Woong-Bin Sur, Jung-Hyang Seung, Byung-Joon Kang, Hyun-Min Kim, Jong-Won Park, See-Hyoung Park, Hee-Myung |
author_facet | Song, Doo-Won Ro, Woong-Bin Sur, Jung-Hyang Seung, Byung-Joon Kang, Hyun-Min Kim, Jong-Won Park, See-Hyoung Park, Hee-Myung |
author_sort | Song, Doo-Won |
collection | PubMed |
description | BACKGROUND: Serum-based parameters are considered non-invasive biomarkers for cancer detection. In human studies, insulin-like growth factor-I and II (IGF-I and IGF-II) and insulin-like growth factor binding protein-3 (IGFBP-3) are useful as diagnostic or prognostic markers and potential therapeutic targets. OBJECTIVES: This study examined the diagnostic utility of circulating IGF-I, IGF-II, and IGFBP-3 levels in healthy dogs and dogs with tumors. METHODS: The serum concentrations of these biomarkers in 86 dogs with tumors were compared with those in 30 healthy dogs using an enzyme-linked immunosorbent assay (ELISA). RESULTS: The ELISA results showed no difference between healthy dogs and dogs with tumors in the serum IGF-II concentrations. On the other hand, there was a significant difference in the circulating IGF-I and IGFBP-3 levels between healthy dogs and dogs with tumors. The concentrations of serum IGF-I (median [interquartile range], 103.4 [59.5–175] ng/mL) in dogs with epithelial tumors were higher than those (58.4 ng/mL [43.5–79.9]) in healthy dogs. Thus, the concentrations of serum IGFBP-3 (43.4 ng/mL [33.2–57.2]) in dogs with malignant mesenchymal tumors were lower than those (60.8 ng/mL [47.6–70.5]) in healthy dogs. CONCLUSIONS: The serum IGF-I and IGFBP-3 levels can be used as diagnostic biomarkers in dogs with tumors. |
format | Online Article Text |
id | pubmed-8636663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Korean Society of Veterinary Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-86366632021-12-13 Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs Song, Doo-Won Ro, Woong-Bin Sur, Jung-Hyang Seung, Byung-Joon Kang, Hyun-Min Kim, Jong-Won Park, See-Hyoung Park, Hee-Myung J Vet Sci Original Article BACKGROUND: Serum-based parameters are considered non-invasive biomarkers for cancer detection. In human studies, insulin-like growth factor-I and II (IGF-I and IGF-II) and insulin-like growth factor binding protein-3 (IGFBP-3) are useful as diagnostic or prognostic markers and potential therapeutic targets. OBJECTIVES: This study examined the diagnostic utility of circulating IGF-I, IGF-II, and IGFBP-3 levels in healthy dogs and dogs with tumors. METHODS: The serum concentrations of these biomarkers in 86 dogs with tumors were compared with those in 30 healthy dogs using an enzyme-linked immunosorbent assay (ELISA). RESULTS: The ELISA results showed no difference between healthy dogs and dogs with tumors in the serum IGF-II concentrations. On the other hand, there was a significant difference in the circulating IGF-I and IGFBP-3 levels between healthy dogs and dogs with tumors. The concentrations of serum IGF-I (median [interquartile range], 103.4 [59.5–175] ng/mL) in dogs with epithelial tumors were higher than those (58.4 ng/mL [43.5–79.9]) in healthy dogs. Thus, the concentrations of serum IGFBP-3 (43.4 ng/mL [33.2–57.2]) in dogs with malignant mesenchymal tumors were lower than those (60.8 ng/mL [47.6–70.5]) in healthy dogs. CONCLUSIONS: The serum IGF-I and IGFBP-3 levels can be used as diagnostic biomarkers in dogs with tumors. The Korean Society of Veterinary Science 2021-11 2021-09-08 /pmc/articles/PMC8636663/ /pubmed/34697923 http://dx.doi.org/10.4142/jvs.2021.22.e77 Text en © 2021 The Korean Society of Veterinary Science https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Song, Doo-Won Ro, Woong-Bin Sur, Jung-Hyang Seung, Byung-Joon Kang, Hyun-Min Kim, Jong-Won Park, See-Hyoung Park, Hee-Myung Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs |
title | Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs |
title_full | Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs |
title_fullStr | Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs |
title_full_unstemmed | Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs |
title_short | Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs |
title_sort | evaluation of circulating igf-i and igfbp-3 as biomarkers for tumors in dogs |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636663/ https://www.ncbi.nlm.nih.gov/pubmed/34697923 http://dx.doi.org/10.4142/jvs.2021.22.e77 |
work_keys_str_mv | AT songdoowon evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs AT rowoongbin evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs AT surjunghyang evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs AT seungbyungjoon evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs AT kanghyunmin evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs AT kimjongwon evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs AT parkseehyoung evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs AT parkheemyung evaluationofcirculatingigfiandigfbp3asbiomarkersfortumorsindogs |